Alchemab Therapeutics is a clinical-stage biotech founded in 2019 that uses its Resiliome™ platform—combining one of the world’s largest fully human antibody databases with AI and lab validation—to identify naturally occurring protective antibodies from disease-resilient individuals. The company has generated a pipeline of first- and best-in-class antibody assets, including ATLX-1282, a first-in-class therapeutic in clinical development for ALS that was licensed to Eli Lilly. Alchemab plans to expand its proprietary antibody dataset from about 500 million sequences to over one billion and to advance additional candidates into clinical development. The company’s platform integrates deep sequencing, AI-derived algorithms, and laboratory validation to characterise candidate antibodies. Alchemab has raised a total of £109 million in Series A financing to date and lists investors such as SV Health Investors, the Dementia Discovery Fund, RA Capital, DCVC Bio, Eli Lilly, Lightstone Ventures, Ono Venture Investment, and Camford Partners. The recent £25 million Series A extension led by the British Business Bank is intended to accelerate its clinical pipeline and database growth.

Total raised

$149M

Funding rounds

4

Latest round

Series A

Latest activity

Jul 2026